Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Systemic steroids and risk of fecal-oral shedding and increased transmission of SARS-CoV-2 in pemphigus cases

Manoj Pawar, MD**1, Mehak Singh, MD**1

**Department of Dermatology, MVP’s Dr. V.P. Medical College & Hospital & Research center, Nashik, India
**Department of Dermatology, JK Medical College & LN Hospital, Bhopal, India

Abstract

Pemphigus and its variants, viz., vulgaris, foliaceous, vegetans, Ig A pemphigus, paraneoplastic pemphigus and Senear-Usher syndrome are rare autoimmune blistering diseases of the skin and/or mucous membranes. The autoantibodies involved in the pathogenesis of pemphigus against desmoglein result in the breach of the skin and mucosal barrier, which acts as the first line of defence against pathogens. In this paper we underscore the importance of the integumentary system as a shield against the acquisition as well as transmission of SARS-CoV-2 virion. We have also made an attempt to delineate the various treatment modalities available and the viral-drug dynamics involved in choosing the optimum therapeutic modality.

To the Editor:

Coronavirus disease 2019 (COVID-19), a serious pulmonary illness caused by novel coronavirus SARS-CoV-2, has become a global pandemic. The outbreak of COVID-19 has made an impact on the management of various autoimmune skin diseases, including pemphigus vulgaris (PV). It is a general consensus that immunosuppressive or biologic treatment should be avoided in patients with active COVID-19 infection.1 Rituximab, the only FDA-approved medication for moderate-to-severe PV, is considered first-line therapy for pemphigus; however, considering its irreversible effect on B-cells, which are active defense cells against COVID-19 infection, it is better to be avoided/postponed during this COVID pandemic.2 Second option, which is still commonly practiced and considered as the first-line therapy in resource-poor settings, is corticosteroids—either in intravenous pulse doses or daily oral doses. As a result of a complete lockdown situation, patients with pemphigus do not have ready access to monthly pulse steroid therapy, and so they may be maintained on an effective daily regimen of oral steroids; however, there are a few concerns about systemic steroids in pemphigus and the risk of transmission of COVID-19.

Transmission

Severe or treatment-naïve cases of PV have mucocutaneous breaches that make them vulnerable to COVID-19 viral contagion, because angiotensin-converting enzyme 2, which is a cell receptor for SARS-CoV-2, is abundantly present in the cutaneous blood vessels and the basal cell layer.3 Once a pemphigus patient is infected with COVID-19, there is a high
chance of increased viral shedding due to both gut barrier dysfunction and increased viral transmission, associated with “aerosolization” of infected fecal matter.4 Recently, a theory for coronavirus entry into cell has been proposed, that is, antibody-dependent enhancement, in which a neutralizing antibody binds to the surface spike protein of coronaviruses like a viral receptor, triggers a conformational change of the spike, and mediates viral entry into cells expressing IgG Fc receptors through canonical viral-receptor-dependent pathways. We speculate that the already primed immune system in PV with increased and marginalized T-cell and B-cell populations at the active sites of PV may increase the virion uptake. Conversely, COVID-19 may increase the epitope spreading phenomenon in PV, leading to increased severity and hence a more vicious circle.5 Managing pemphigus patients with a high viral load of COVID-19 may also increase the chances of nosocomial spread to health care workers.

The gut mucosal damage triggered by corticosteroids may increase the susceptibility of PV patients to COVID-19, as feco-oral transmission has been established as a route of transmission of SARS-CoV-2.4,6 Corticosteroids are also linked to a disruption of microbiome leading to a breach in the protective gut biological mantle. These protective bacteria serve as a biologic shield to combat the contagion.6 Systemic steroids may cause breach in the biologic, physical, or even immunologic barriers of the gut, eventually leading to a so-called leaky gut, from which the viral particles can disseminate into the bloodstream (Figure 1). Opposed to this concept, the bioavailability and thus efficacy of oral steroids in pemphigus patients with mucosal involvement may be impaired due to gut mucosal disintegrity and gut dysbiosis.6,7 Pemphigus patients with severe upper gastrointestinal and oral mucosal involvement may experience troublesome swallowing and associated decreased compliance.7 (See Table 1).
| Drug          | Washout Period (Increased Susceptibility Period For COVID-19) | Pros                                                                 | Cons                                                                 | Expert Guidelines (During COVID) |
|--------------|-------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|---------------------------------|
| Rituximab    | 1 year (earliest 5-6 months)                                | • First-line adjuvant (EADV guideline) and second line therapy       | • Infusion-related adverse effects                                   | • Definite high risk patients: require shielding $ |
|              |                                                              | • Steroid sparing                                                     | • Muco-cutaneous reactions                                           |                                 |
|              |                                                              | • Gold standard therapy in non-resource limiting settings             | • Hepatitis B reactivation with fulminant hepatitis; progressive, multifocal leukoencephalopathy; other viral and opportunistic infections |                                 |
|              |                                                              | • Can be stopped abruptly                                             | • Cardiac arrhythmias; renal toxicity; bowel obstruction and perforation; |                                 |
|              |                                                              | • Specific immunosuppression, i.e., humoral immunity suppression      | • Hematologic disturbances, such as lymphopenia, neutropenia, and anemia |                                 |
|              |                                                              | • Few adverse effects, especially lower incidence of metabolic side effects. | • Contraindicated in pregnant or breastfeeding women and in individuals with hepatitis B or C, HIV, or sepsis |                                 |
|              |                                                              | • Few follow ups required                                              | • B cell depletion: increased susceptibility to infections            |                                 |
|              |                                                              |                                                                     | • Risk of thromboembolism                                             |                                 |
|              |                                                              |                                                                     | • Might decrease the efficacy of future COVID-19 vaccine             |                                 |
|              |                                                              |                                                                     | • Expensive. Not the first line in resource poor set ups              |                                 |
| Oral corticosteroids | 2 weeks                                      | • First line therapy in all settings                                  | • Non-specific immunosuppression                                      | • Corticosteroid dose of $ \geq 20 \text{ mg (or 0.5 mg/kg ) prednisolone (or equivalent) per day for more than 4 weeks; definite high risk-need shielding} $ |
|              |                                                              | • Rapid disease control                                               | • Adrenal suppression                                                |                                 |
|              |                                                              | • Cheaper                                                            | • Requires careful tapering                                           |                                 |
|              |                                                              | Recent study indicates the potential reduction of mortality in severe COVID-19 cases by using low dose dexamethasone,$^{17}$ | • Metabolic side effects precludes long term use                      |                                 |
| Azathioprine | 3 months (approx.)                                         | • First-line adjuvant                                                 | • Measurement of TPMT activity before initiation                     | • If patient has co-morbidities or any immunosuppressant or biologics/ monoclonals or novel small molecule immunosuppressants combined: Definite high risk $^*$ to be advised to shield $^\S$ |
|              |                                                              | • Steroid sparing                                                    | • Regular monitoring required                                         |                                 |
|              |                                                              |                                                                     | • Myelosuppression                                                   |                                 |
|              |                                                              |                                                                     | • Hepatotoxicity, pancreatitis, and arthralgia.                      |                                 |
|              |                                                              |                                                                     | • Long-term: increases the risk of infections and neoplasia.         |                                 |
| Drug                        | Washout Period (Increased Susceptibility Period For COVID-19) | Pros                                                                 | Cons                                                                                                                                                                                                 |
|---------------------------|-------------------------------------------------------------|----------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Mycophenolate mofetil     | 3 months (approx.)                                          | • First-line adjuvant                                                    • Contraindicated in Pregnancy and breast feeding                     | • Gastrointestinal disturbances                                                                                          • If patient has co-morbidities * or any immunosuppressant or biologics/monoclonals or novel small molecule immunosuppressants combined: Definite high risk – to be advised to shield § |
|                           |                                                              | • Steroid sparing                                                       | • Genitourinary symptoms                                                  • If patient has co-morbidities * or any immunosuppressant or biologics/monoclonals or novel small molecule immunosuppressants combined: Definite high risk – to be advised to shield § |
|                           |                                                              |                                                                      | • Hematologic abnormalities                                               • If patient has co-morbidities * or any immunosuppressant or biologics/monoclonals or novel small molecule immunosuppressants combined: Definite high risk – to be advised to shield § |
|                           |                                                              |                                                                      | • Opportunistic infections                                                • Requires continuous monitoring • Cost                          |                                                                                                                                                                                         |
| Cyclophosphamide          | 3 months (data extrapolated from Azathioprine/MMF)         | • Second-line adjuvant (EADV guideline)                                | • Poor safety profile                                                     • If patient has co-morbidities * or any immunosuppressant or biologics/monoclonals or novel small molecule immunosuppressants combined: Definite high risk – to be advised to shield § |
|                           |                                                              | • Third-line therapy (BAD guideline)                                    | • GI disturbances                                                          • If patient has co-morbidities * or any immunosuppressant or biologics/monoclonals or novel small molecule immunosuppressants combined: Definite high risk – to be advised to shield § |
|                           |                                                              | • Steroid sparing                                                       | • Skin, hair and nail changes                                              • If patient has co-morbidities * or any immunosuppressant or biologics/monoclonals or novel small molecule immunosuppressants combined: Definite high risk – to be advised to shield § |
|                           |                                                              | • Used in unresponsive or recalcitrant cases                           | • Hemorrhagic cystitis                                                     • Transitional cell carcinoma of urinary bladder                  |                                                                                                                                                                                         |
|                           |                                                              |                                                                      | • Pregnancy Category D and contraindicated in breastfeeding             • Azoospermia, and infertility                             |                                                                                                                                                                                         |
|                           |                                                              |                                                                      | • Both humoral and cellular immunity suppression.                      • Pregnancy Category D and contraindicated in breastfeeding             |                                                                                                                                                                                         |
|                           |                                                              |                                                                      | • Insufficient data for efficacy in PV-not recommended by BAD and EADV guidelines |                                                                                                                                                                                         |
|                           |                                                              |                                                                      | • If patient has co-morbidities * or any immunosuppressant or biologics/monoclonals or novel small molecule immunosuppressants combined: Definite high risk – to be advised to shield § |                                                                                                                                                                                         |
|                           |                                                              |                                                                      | • Does not warrant high risk status € in absence of comorbidities.     |                                                                                                                                                                                         |
|                           |                                                              |                                                                      | • Social distancing as with normal population.                           |                                                                                                                                                                                         |
|                           |                                                              |                                                                      | • If patient has co-morbidities * or any immunosuppressant or biologics/monoclonals or novel small molecule immunosuppressants combined: Definite high risk – to be advised to shield § |                                                                                                                                                                                         |
| Dapsone                   | 1-2 week                                                    | • Second-line adjuvant                                                    | • Questionable efficacy                                                   • Does not warrant high risk status € in absence of comorbidities.                               |                                                                                                                                                                                         |
|                           |                                                              | • Useful in mild cases                                                  | • Hemolytic anemia.                                                        |                                                                                                                                                                                         |
|                           |                                                              | • Established safety profile                                             | • Requires regular monitoring                                             |                                                                                                                                                                                         |
| Methotrexate              | 2-3 days                                                    | • Second-line adjuvant                                                    | • GI, haematologic side effects                                           |                                                                                                                                                                                         |
|                           |                                                              |                                                                      | • Infections, including pneumonia and reactivation of tuberculosis.      |                                                                                                                                                                                         |
|                           |                                                              |                                                                      | • Pregnancy category X                                                    |                                                                                                                                                                                         |
| IVIG                      | Not applicable as no immunosuppression                      | • Second-line adjuvant (EADV guidelines )                              | • Questionable efficacy                                                   |                                                                                                                                                                                         |
|                           |                                                              | • Third-line therapy by the BAD guidelines.                             | • Infusion reactions                                                      |                                                                                                                                                                                         |
|                           |                                                              |                                                                      | • If patient has co-morbidities * or any immunosuppressant or biologics/monoclonals or novel small molecule immunosuppressants combined: Definite high risk – to be advised to shield § |                                                                                                                                                                                         |
|                           |                                                              |                                                                      | • Does not warrant high risk status € in absence of comorbidities.     |                                                                                                                                                                                         |
| Hydroxychloroquine (HCQ)  | 90 days (not applicable)                                   | • Reports of efficacy against and as a preventive therapy for COVID-19 | • Retinopathy                                                             |                                                                                                                                                                                         |
|                           |                                                              |                                                                      | • Asian patients: Ocular toxicity outside of macula: visual field testing be |                                                                                                                                                                                         |
|                           |                                                              |                                                                      | • Does not warrant high risk status € in absence of comorbidities.     |                                                                                                                                                                                         |
| Drug                          | Washout Period (Increased Susceptibility Period For COVID-19) | Pros                                                                 | Cons                                                                 | Expert Guidelines (During COVID) |
|------------------------------|---------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------|
| Plasmapheresis               | Not applicable                                                | • Second-line adjuvant                                               | • Invasive                                                          | Preventive and therapeutic in COVID-19 |
|                              |                                                               | • Safer                                                             | • Expensive                                                         |                                  |
|                              |                                                               | • Helpful as an adjuvant in acute phase                           | • Available only in tertiary centres                               |                                  |
|                              |                                                               | • Same as plasmapheresis                                           | • Same as plasmapheresian                                          |                                  |
|                              |                                                               |                                                                    | • Only added advantage being avoidance of substitution fluids      |                                  |
| Rilzabrutinib (formerly PRN 1008) | Not disclosed                                                   | • Highly targeted therapy: Agammaglobulinemia tyrosine kinase inhibitors | • Phase 3                                                           | Does not warrant high risk status in absence of comorbidities. |
|                              |                                                               | • Oral administration                                               | • No long term data                                                 | Therapeutic in COVID-19          |
|                              |                                                               |                                                                    | • Cannot be used in pregnant/lactating women                       |                                  |
|                              |                                                               |                                                                    | • Expensive                                                         |                                  |
|                              |                                                               |                                                                    | • Non-availability                                                   |                                  |
| Tocilizumab                  | Cocentration dependent and not applicable here                 | • Phase 2 trial for COVID pneumonia                                | • Efficacy not established in PV                                   |                                  |
|                              |                                                               | • Useful in paraneoplastic pemphigus                               | • Reports of tocilizumab induced pemphigus                          |                                  |
|                              |                                                               | • Anecdotal reports inPV                                            |                                                                    |                                  |
| Other Investigational Drugs: | Not disclosed                                                   |                                                                    |                                                                    |                                  |
| Ofatumumab                   |                                                               |                                                                    |                                                                    |                                  |
| Veltuzumab                   | Type 1 anti-CD20 monoclonal antibodies                         |                                                                    |                                                                    |                                  |
|                              | Type 1 humanized anti CD20 monoclonal antibody: administered subcutaneously, resulting in lower side effects than intravenous RTX |                                                                    |                                                                    |                                  |
| Obinutuzumab                 | Type II humanized anti-CD20                                   |                                                                    |                                                                    |                                  |

*Note:* The table provides a summary of drug washout periods, increased susceptibility periods for COVID-19, and associated pros, cons, and expert guidelines. The table includes drugs such as Plasmapheresis, Rilzabrutinib, Tocilizumab, Ofatumumab, Veltuzumab, and Obinutuzumab. The table highlights key considerations such as safety, availability, and efficacy in the context of COVID-19.
**Drug Washout Period (Increased Susceptibility Period For COVID-19)**

| Drug     | Washout Period                                                                 | Pros                                                                 | Cons                                                                 |
|----------|--------------------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|
| Belimumab| monoclonal antibody                                                            |                                                                      |                                                                      |
|          | Monoclonal human IgG1 antibody                                                  |                                                                      |                                                                      |
|          | bwhich target BAFF and a proliferating-induced ligand (APRIL)                  |                                                                      |                                                                      |
| Atacicept| Human recombinant fusion protein, which target BAFF and a proliferating-induced ligand (APRIL) |                                                                      |                                                                      |
|          | Ty                                                                              |                                                                      |                                                                      |

* Co-morbidities: Age >60 years, pregnancy, chronic smokers or tobacco chewers, diabetes mellitus, severe hypertension, any pre-existing ischemic heart disease, respiratory system compromise, liver disease, kidney disease, internal malignancies.

§ Shielding: Individuals at highest clinical risk from coronavirus (COVID-19) should:

➢ Stay in home isolation for as long as possible with not more than one stint outside per day.
➢ Exercise extra precautions to minimise contact with others by keeping 2 metres apart if they opt to go out.
➢ Interaction to be limited to members of their own household or at the most one person/essential caretaker (same person everytime) from outside (maintain a social bubble).
➢ Should not attend and avoid gatherings.
➢ Strictly avoid contact with symptomatic and/or known cases of COVID-19.
➢ Essential carers coming to home or other members of family should:
  • follow advice on good hygiene and frequent hand washing for 20 seconds or sanitiser; avoid touching face.
  • At home also practice social distancing by keeping 2 meters or 3 steps away.
  • Minimise the time other people living with the patient spend in shared spaces such as kitchens, bathrooms and sitting areas, and keep shared spaces well ventilated with frequent cleaning.
  • Try and sleep in a different bed where possible.

(Public Health England guidance published on 21 March 2020.)

$ Advised to shield (moderate risk) only if other concerns or high-risk circumstances/co-morbidities*, however, those not requiring shielding, on immunosuppressant therapy, are termed ‘vulnerable person’ advised to be particularly stringent with certain social distancing measures.

* Definite high risk: As delineated in the table some agents confer high risk stratification.

$ These agents have either been used or have a potential to be used in the treatment of COVID-19. Some drugs like HCQ might have a preventive role in COVID-19 infection.
Corticosteroids

Corticosteroids can be considered a double-edged sword in the COVID-19 situation. Systemic steroid-induced immunosuppression impairs induction of Interferon Type 1 (IFN-1) responses to various respiratory viruses, including COVID-19. In opposition, steroids have shown some beneficial effects in hyperinflammatory conditions associated with COVID-19, that is, cytokine storm, acute respiratory distress syndrome, and sepsis. In any event, abrupt cessation of corticosteroids is not advised due to the risk of adrenal suppression.

A recent international registry has shown that patients with inflammatory bowel disease treated with corticosteroids had increased severity of COVID-19, compared with patients receiving such tumor-necrosis-factor-alpha antagonists as adalimumab (Humira). Physicians should assess patients receiving such tumor-necrosis-factor-alpha antagonists had increased severity of COVID-19, compared with the eye. Gut 2020;69:973-974.

References

Declaration of competing interest

No conflict of interest.

References

1. Torres T, Puig L. Managing cutaneous immune-mediated diseases during the COVID-19 pandemic. Am J Clin Dermatol 2020;21:307-311.
2. Shakshouk H, Daneshpazhooh M, Murrell DF, et al. Treatment considerations for patients with pemphigus during the COVID-19 pandemic. J Am Acad Dermatol 2020;82:e235-e236.
3. Hamming I, Timens W, Bullthuis ML, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004;203:631-637.
4. Ng SC, Tilg H. COVID-19 and the gastrointestinal tract: more than meets the eye. Gut 2020;69:973-974.
5. Wan Y, Shang J, Sun S, et al. Molecular mechanism for antibody-dependent enhancement of coronavirus entry. J Virol 2020;94:1-15.
6. Black HE. The effects of steroids upon the gastrointestinal tract. Toxicol Pathol 1988;16:213-222.
7. Rao PN, Samarth A, Aurangabadkar SJ, et al. Study of upper gastrointestinal tract involvement in pemphigus by esophago-gastro-duodenoscopy. Indian J Dermatol Venereol Leprol 2006;72:421-424.
8. Ritchie AL, Singanayagam A. Immunosuppression for hyperinflammation in COVID-19: a double-edged sword? Lancet 2020;395:1111.
9. World Health Association. Coronavirus disease 2019 (COVID-19) situation report – 61. Available at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200322-sitrep-62-covid-19.pdf. Accessed April 20, 2020.
10. Brenner EJ, Ungaro RC, Geary RR, et al. Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry [e-pub ahead of print]. Gastroenterology. doi: https://doi.org/10.1053/j.gastro.2020.05.032, accessed 06/11/2020.
11. Hertl M, Jedlickova H, Karpati S, et al. Pemphigus. S2 Guideline for diagnosis and treatment – guided by the European Academy of Dermatology and Venerology (EADV) in cooperation with the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol 2015;29(3):405-414.
12. Harmun KE, Brown D, Exton LS, et al. British Association of Dermatologists’ guidelines for the management of pemphigus vulgaris 2017. Br J Dermatol 2017;177(5):1170-1201.
13. Maglie R, Didona D, Eming R, et al. Pemphigus: current and future therapeutic strategies. Front Immunol 2019;10:1418, https://doi.org/10.3389/fimmu.2019.01418.
14. Bad.org.uk. https://www.bad.org.uk/shared/get-file.ashx?itemtype= document&id=6674 Published 2020. Accessed June 14, 2020.
15. Hayashida MZ, Pinheiro JRS, Enokihara MMSES, et al. Biologic therapy-induced pemphigus. An Bras Dermatol 2017;92(4):591-593, https://doi.org/10.1590/abd1806-4841.20176481.
16. England.nhs.uk. https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/03/20200401-FAQs-Patients.pdf Published 2020. Accessed June 16, 2020.
17. Fadel R, Morrison AR, Vahia A, et al. COVID-19 Management Task Force, Early Short Course Corticosteroids in Hospitalized Patients with COVID-19. Clin Infect Dis 2020. doi:10.1093/cid/ciaa601. ciaa601.
18. Hernandez AV, Roman YM, Pasupuleti V, et al. Hydroxychloroquine or chloroquine for treatment or prophylaxis of COVID-19: a living systematic review. Ann Intern Med 2020 May 27. (Epub ahead of print).
19. Dogan L, Kaya D, Sarikaya T, et al. Plasmapheresis treatment in COVID-19-related autoimmune meningoencephalitis: Case series [published online ahead of print, 2020 May 7]. Brain Behav Immun 2020, https://doi.org/10.1016/j.bbi.2020.05.022. S0889-1591(20)30803-5.